About us

Simris is a biotechnology company committed to transforming cancer treatment through its proprietary pipeline of next-generation ADC payloads. These payloads are born from world-class cyanobacterial science, proprietary conjugation methods, and collaborations with leading research institutions.

We are currently optimising novel Microcystin toxin variants for use in advanced ADCs, targeting both haematologic and solid tumours. 

Our research team leverages close to 20 years of cyanobacteria expertise and our exclusive strain library to efficiently develop and scale novel payloads. This unique platform gives Simris a significant competitive edge in the emerging ADC landscape.

We operate a collaboration-first strategy, building value through partnerships with biopharma companies committed to delivering the next leap in targeted cancer therapies.

Simris Group is headquartered in Malmö, Sweden, and is listed on the Nasdaq First North Growth Market (SIMRIS, ISIN: SE0008091664).

Loading...

© 2026 Simris Group · Pioneering algae biotech since 2011. all rights reserved.

Simris Alg AB shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664. Certified Adviser is Amudova AB, telephone: +46 8 546 017 58, email: info@amudova.se.